- 1 Implementation of Point of Care HIV Viral load monitoring
- 2 for people living with HIV in Low and Middle-income
- 3 Countries: A systematic review on implementation research
- 4 outcomes.
- 5 Perry Msoka^{1,2,3}, Iraseni Swai^{1,3,4}, Kennedy Ngowi¹, Ria Reis^{3,5}, Andreja Lekic², Blandina T.
- 6 Mmbaga^{1,6,7}, Anita Hardon^{3,8}, Marion Sumari-de Boer^{1,3,6,8}
- 8 Affiliations:

18

19

- 9 1. Kilimanjaro Clinical Research Institute, Moshi, Tanzania
- 2. Amsterdam Institute for Social Science Research, Amsterdam, the Netherlands
- 3. Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands
- 4. UMC Amsterdam, location AMC, Amsterdam, the Netherlands
- 5. The Children's Institute, University of Cape Town, Cape Town, South Africa
- 6. Kilimanjaro Christian Medical University College, Moshi, Tanzania
- 7. Kilimanjaro Christian Medical Centre, Moshi, Tanzania
- 8. Knowledge, Technology and Innovation Chair group, Social Sciences Department,
- 17 Wageningen University & Research, the Netherlands
- 20 Corresponding author: Perry Cyril Msoka. Kilimanjaro Clinical Research Institute
- 21 Moshi, Kilimanjaro, Tanzania
- p.msoka@kcri.ac.tz

Abstract

35 Background

34

37

38

39

40

41

42

48

49

51

55 56

57

58

59

60

61

62

63

Viral load monitoring has rapidly increased among people living with HIV(PLHIV) in low- and

middle-income countries (LMICs), resulting in an increased laboratory workload. The use of

innovative Point of Care (PoC) or near Point of Care (n)PoC HIV Viral Load (HIV VL)

monitoring has enabled improved patient care, a reduction in laboratory workload, improved

clinic retention and reduced turnaround time of results. However, implementation bottlenecks of

such methods are uncertain, especially when PoC or (n)PoC is implemented in remote areas in

low-volume clinics. The main aim of this study was to review implementation research outcomes

of (n)PoC HIV VL monitoring for PLHIV in LMICs.

44 Methodology

We qualitatively synthesised peer-reviewed papers to explore implementation research outcomes

46 (IROs) of (n)PoC HIV VL monitoring. We identified studies published between January 2013

and June 2024. We used the IROs described by Proctor et al., which are acceptability, adoption,

appropriateness, cost, feasibility, fidelity, penetration and sustainability. We searched using the

following Mesh terms: Point of care testing, HIV, viral load, acceptability, patient acceptance of

50 health care, adoption, facilities and services utilisation, appropriateness, cost, feasibility, fidelity,

penetration, coverage, sustainability and continuity of patient care through PubMed, Cochrane

and Scopus. The PRISMA diagram in Figure 1 presents the selection process of included papers.

53 Results

Twenty-five studies reported implementation outcomes of PoC or (n)PoC HIV VL monitoring.

Near PoC HIV VL monitoring using GeneXpert is considered acceptable to patients and

healthcare providers. Point of care HIV VL monitoring using mPIMA was feasible as patients

received the results the same day. From a health service provider's perspective, PoC HIV VL

monitoring was acceptable because it influenced patients to accept the illness and adhere to

medication. Additionally, there was high testing coverage in routine PoC HIV VL monitoring

centres. Fidelity was questionable in some settings due to (n)PoC HIV VL monitoring results not

being delivered as intended. Additionally, we found in several studies that the (n)PoC costs are

higher than standard of care test, USD 54.93 per test, at low testing volume clinics conducting

20VL tests per month compared to costs of USD 24.25 at high testing volume clinics conducting

100VL tests per month. However, costs are expected to be lower when (n)PoC HIV VL monitoring is scaled up and targeted for those at risk. Conclusion Implementation of PoC or (n)PoC testing for HIV viral load monitoring is acceptable and feasible and can reach a vast population. However, higher costs, limited fidelity, lower penetration and limited sustainability may hinder using (n)PoC testing in improving patient care and health outcomes. More knowledge and training should be implemented to overcome these challenges. Keywords: Point of Care HIV Viral Load monitoring; People living with HIV; systematic review; Implementation research outcomes; Low and middle-income countries Introduction Globally, an estimated 39.9 million people were living with Human Immunodeficient Virus (HIV) in 2023, of whom 77% of adults and 57% of children accessed antiretroviral therapy (ART).(1) The Joint United Nations Programme on HIV and AIDS (UNAIDS) aims to reach 95-

95-95 targets by 2030 that 95% of people living with HIV (PLHIV) know their HIV status, 95% 90 of diagnosed PLHIV receive antiretroviral therapy (ART), and 95% of PLHIV receiving ART 91 92 attain viral suppression below 1,000 copies/ml.(2) To reach these goals, the World Health Organization (WHO) emphasizes that all PLHIV receive ART and routine HIV viral load (VL) 93 testing to monitor treatment response, adherence and virologic suppression.(3) 94 However, monitoring the VL of PLHIV on ART in resource-limited settings is still challenging 95 96 due to limited infrastructure, shortage of skilled staff, loss of samples, an inefficient system of 97 providing results and patients being lost to follow-up.(4) To overcome those challenges, WHO has advocated for integrating Point of care HIV Viral load (PoC HIV VL) monitoring in HIV 98 99 care services.(5,6) 100 Point of Care HIV VL monitoring entails testing at the point where healthcare is provided. The 101 results can be given on the same day. Also, it can usually be performed by non-trained staff.(7) Near Point of Care HIV VL monitoring is testing in laboratories close to treatment facilities, 102 103 while still improving the turnaround time from sampling to result.(8) The current PoC HIV VL 104 assays that are commercially available or in late development include the PoC HIV assay of mPIMA by Abbott, and the (n)PoC HIV assays SAMBA by Diagnostics for the Real World and 105 GeneXpert HIV 1 by Cepheid.(9) 106 107 Several studies have been conducted on the performance of PoC HIV VL monitoring. In Mozambique, mPIMA was found to have a high sensitivity of 95% and specificity of 96.5% to 108 109 identify virological failure at the threshold of 1000 copies/ml when a standard conventional plasma test was used as the golden standard.(10) In addition, a study evaluating the performance 110 of SAMBA in Malawi and Uganda found it to be accurate in differentiating patients who had a 111 112 VL below or above 1000 copies/ml.(11) Furthermore, a systematic review study from developed and developing countries found that PoC 113 114 testing is preferable to centralized testing, with a sensitivity of 93.3% - 100% and specificity of 99.5%- 100% for Early Infant Diagnosis (EID), acute HIV infection diagnosis, or VL 115 116 monitoring.(12) 117 Despite the good performance of PoC HIV VL monitoring in previous studies, several challenges exist. A systematic review of the performance and clinical utility of POC HIV viral load testing 118

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

in resource-limited settings observed that there is a need for constant electricity for the machine to function and a temperature control room for sample processing and storage. (12) Other reported challenges of PoC HIV VL monitoring are device operation by untrained staff, routine device maintenance, and the high costs of a PoC test. All these may hamper the implementation of PoC HIV VL monitoring. Given the above-reported challenges, future studies should explore solutions to overcome possible implementation challenges. Proctor and colleagues (2011) designed a framework that describes eight distinct implementation outcomes to guide the successful implementation of innovations: acceptability, adoption, appropriateness, feasibility, fidelity, implementation costs, penetration and sustainability. Acceptability is the perception among stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. Secondly, adoption is the intention, initial decision, or action to try or employ an innovation or evidencebased practice. Thirdly, appropriateness is the perceived fit of the innovation to address a particular issue or problem. Fourthly, the cost is the financial effect of an implementation effort. It may include charges for treatment delivery, implementation strategy and use of the service setting. Fifthly, feasibility is how a new treatment or innovation can be successfully used or carried out within a given agency or setting. Sixthly, fidelity is defined as the extent to which an intervention was implemented as prescribed in the original protocol or as the program developers intended. Seventhly, penetration is integrating practice within a service setting and its subsystems. Lastly, sustainability is how a newly implemented intervention is maintained or institutionalised within a service setting's ongoing, stable operations. These implementation outcomes can give insights into challenges and assist in developing strategies to be investigated in future pragmatic trials.(13) In this systematic review, we use the Proctor framework to explore implementation research outcomes of (n)PoC HIV VL monitoring for PLHIV in LMICs through a qualitative synthesis of peer-reviewed papers. The specific objectives were to review existing evidence on (1) the acceptability, (2) the adoption, (3) the appropriateness, (4) the cost, (5) the feasibility, (6) the fidelity, (7) the penetration and (8) the sustainability of (n)PoC HIV VL monitoring.

Methodology

- 149 Using the reporting items in systematic review guideline(14) we qualitatively synthesised
- scientific papers to explore the implementation research outcomes (IROs) of PoC HIV VL
- monitoring for PLHIV. We used the Proctor framework of IROs and pre-defined topics to define
- the search terms.(13)
- 153 Literature search

148

- The initial broad relevant MESH terms were defined based on the terms 'PoC testing', 'HIV' and
- 155 'Viral load'. We viewed the proper entry terminology for the IROs: Acceptability, Adoption,
- Appropriateness, Cost, Feasibility, Fidelity, Penetration and Sustainability. After defining these
- terms, we searched for the terms in June 2024 using a combination of the MESH and entry
- terms. A detailed search strategy is presented in the S1 Table.
- Three databases were searched for publications published between January 2013 and June 2024:
- 160 (1) PubMed, (2) Cochrane and (3) Scopus. After this, we scanned the reference list of each
- obtained publication found through the above search for additional publications that could fit our
- search criteria.
- 163 Study selection

- Publications were included based on the following criteria:
- Quantitative, including trials or qualitative studies.
- Original papers.
- Focus on (n)PoC VL monitoring.
- A publication should at least describe one of the IROs as described by Proctor.
- 170 We used Covidence software https://support.covidence.org/help/how-can-i-cite-covidence to
- 171 select and organise manuscripts and data extraction. The publications were identified and
- imported with a librarian (A) into the software for selecting eligible publications. After collecting
- publications from PubMed, Cochrane and Scopus, the titles and abstracts of identified studies
- were screened by two reviewers (PM, MS) for relevance. Any disagreements during the
- screening of titles and abstracts were resolved through discussion. In case of doubt that a
- publication met the criteria, it was included for full-text assessment to assess the eligibility. The
- full-text assessment of the quality and risk of bias of all included publications was performed by

two reviewers (PM, MS). We used the Newcastle Ottawa scale (NOS) to assess the risk of bias. (15) The tool assessed the bias in three categories which are: selection, comparability, and outcome or exposure. A star system was used: a score of seven to nine stars was considered a low risk of bias, four to six stars were considered an "unclear risk of bias", and three or fewer stars were considered a "high risk of bias". The study was considered of low quality if we found it to have a high risk of bias.

All manuscripts included in the full-text assessment were judged based on the quality of the paper using twenty-seven criteria selected from the PRISMA guidelines for reporting systematic reviews.(16) The PRISMA checklist can be found in the S2 Table. The twenty selected criteria

covered the following items:

178

179

180

181

182

183

184

185

186

187

188

189

191

192

193

194

195

196

197

198

199

200

201

202

206

- The abstract was comprehensive.
 - The objective did clearly state the specific aims of the study.
- The rationale was based on a well-described literature review.
 - The methodology clearly described qualitative or quantitative methods, research setting and participants, methods and data collection procedures.
 - Ethical issues were assessed by judging informed consent procedures, voluntary participation, no harm, confidentiality and anonymity.
 - The analysis and results had to be realistic to achieve the required study objective.

Exclusion criteria were:

- Studies with outcomes that were not relevant to our review.
- Studies describing interventions outside of our area of interest.
- Studies and reviews of papers published before 2013 in which PoC VL testing was not widely available or implemented.
 - Protocol studies.

203 Data extraction and management

- One reviewer (PM) extracted the data. The following information was extracted from the
- 205 included studies:
 - Country where the study was performed

Study design classified as clinical trials, cohort, qualitative or modelling studies 207 208 Study funding sources Population description 209 Study period, start and end date 210 Inclusion and exclusion criteria 211 212 Methods of recruitment of the participants 213 Implementation of research outcomes (IROs) investigated 214 215 Ethical Approval and Informed Consent 216 The review was registered on the PROSPERO registry for systematic reviews. (PROSPERO 217 2023 CRD42023394668). The review did not involve collecting new data from human subjects. 218 Therefore, ethical approval and informed consent were not required. 219 Results 220 221 Three hundred and thirteen studies were found through the initial search of PubMed, Scopus and Cochrane, and an additional five studies were found through scanning the reference lists. Forty-222 223 four duplicate studies were removed from the 318 studies. As a result, 274 studies were screened for eligibility based on title and abstract. From that, 240 irrelevant studies were excluded because 224 225 the publications focused on something other than (n) PoC VL monitoring. Thirty-four studies were assessed on eligibility by reading the full text of the paper. We found that nine studies were 226 227 not eligible: three had irrelevant outcomes for our review, three described interventions outside 228 our area of interest, and three had wrong study designs, as detailed in the S3 Table. This led to 25 229 studies being included in the final review, as shown in Table 1. The PRISMA diagram showing 230 detailed information on search results and the selection process is presented in S1 Figure. 231 232 233 234 235

Study characteristics Twenty-five papers were included in this systematic review.(17–41)Among the studies, seventeen quantitative studies,(18,19,21,22,24–28,30–32,34,36–38,41) six were qualitative studies, (20,29,33,35,39,40) and two were mixed methods studies. (17,23)

Table 1. Characteristics of included studies.

Author/Year/ Country	Study design and setting	Collection	Type of POC test	Acceptability A	Adoption	s	(High/	Feasibility	Fidelity	Penetration	Sustainability
		method	nPoC PoC				low)				
Boyce et al. (2023) Uganda	Open-label, pilot study in lower-level health centre in rural Uganda	Quantitative	GeneXpert					(n)PoC test was more successful than centralized testing due to a reduction in time to results			
Reif et al. (2022) Haiti	Randomized control trials included HIV AIDS clinic	Quantitative met hod	GeneXpert	The majority of patients receive results the same day and immediate counselling							
Tembo et al. (2022) Lusaka, Zambia	Purposive sampling included six health facilities	Qualitative met hod	mPIMA	Patients were influenced to accept the illness and adhere to medication			Low costs of PoC test as the test was done or the spot	5 1			

Author/Year/ Country	setting	Data Collection	Type of PO	C test	Acceptability	Adoption	Appropriatenes s	Cost (High/	Feasibility	Fidelity	Penetration	Sustainability PoC or (n)PoC
		method	nPoC	РоС	-			low)				
Boeke et al. (2021) Cameroon, Congo, Senegal, Kenya, Tanzania, Zimbabwe, Malawi	Retrospective Study included 57 Public- sector health facilities	Quantitative	GeneXpert	mPIMA			High perceived fit of PoC VL monitoring results available at the PoC or (n)PoC					test program to be maintained there is a need
Bulteryrs et al (2021) Kenya	•	Mixed Methods	GeneXpert					High (n) PoC test costs USD 54.93 in low-volume clinics and a low-cost USD 24.25 in high-volume clinics	Low feasibility in some settings that shared the same instrument caused delays in VL results			for clear protocol diagnostic pathways

Author/Year/ Country	Study design and setting	Collection	Type of PC	OC test	Acceptability	Adoption	Appropriatenes s	Cost (High/	Feasibility Fidelity	Penetration	Sustainability	s made a
		method	nPoC	РоС				low)				availa
_	Cohort study included four HC, one DH, one RH	Quantitative	SAMBA 1 VL			Turnaround time within a short period from blood draw to results was reduced			(n)PoC test was more successful than centralized testing	Manpower insufficient and high workload	(n)PoC test in clinics with challenges of staff availabilit and power	ble under a SC-BY 4.0 Inter
Sharma et al. (2021) South Africa	Randomized control trials included large public clinic	Quantitative met hod	GeneXpert	t	The majority of patients receive results the same day and immediate counselling						(n)PoC test increased in healt hcare settings, providing adequate care according to patient needs	ildsir
Wang et al. (2022) Malawi and Zimbabwe	Quantitative study in 18 health facilities	Clinic register and patient charts	GeneXpert	t					Multidisea Lack of se tool was training to highly implement feasible to well (n)PoC scale up test			the preprint in perpetu

	Study design and setting	Data Collection	Type of PO	C test	Acceptability Adoption	Appropriatenes s	Cost Feasibility (High/	Fidelity	Penetration Sustainability
		method	nPoC	РоС			low)		
	Cohort study included healthcare facilities in		GeneXpert	mPIMA			Low costs in		
Southern Zambia	Southern Zambia						PoC or (n)PoC		
Zallibia							test		
							including the test		
							to		
							confirm treatme		
							nt failure		
							and shifting		
							to		
							second- line ART		

Ganesh et al.

Observation study

health facilities

(2021) Malawi included two large

Quantitative GeneXpert

met ho d

286

287

288

289

regimen

(n)PoC test

was more

successful than centralized testing

Author/Year/ Country	Study design and setting	Data Collection	Type of PO	C test	Acceptability	Adoption	Appropriatenes s	Cost (High/	Feasibility	Fidelity	Penetration	Sustainability
		method	nPoC	РоС				low)				
Villa et al.(2020) Ghana	Prospective pilot study included large hospitals	Quantitative	GeneXpert		Same-day result reduces drug resistance							
Drain et al. (2020) South Africa	Randomized control trials included large urban clinic	Quantitative method	GeneXpert	mPIMA	PoC or (n)PoC test improves HIV care and increases ART adherence monitoring				PoC or (n)PoC test shows no delays in diagnosis and sufficient manpower			Sustainability
Kufa et al. (2020) South Africa	Prospective Feasibility included four tertiary obstetric units	Qualitative method	GeneXpert	mPIMA					Multidisea se tool was highly feasible to scale up HIV testing		Nurses are supported in managing stable patients through guidelines	To mentage notice
Msimango et al. (2020) South Africa	Randomized control trial included research clinic	Qualitative method	GeneXpert		(n)PoC test minimised the frequency of clinic visits for high-risk patients		Low appropriatenes s of (n) PoC test in public health facilities with large numbers of people					

ر It is made ayallable under a CC-BY 4.0 International license .	(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the	medRxiv preprint doi: https://doi.org/10.1101/2024.11.04.24316630; this version posted November 5, 2024. The copy
Se.	ense to display the preprint in perpetuity.	2

Author/Year/ Country	Study design and setting	Data Collection	Type of POO	test	Acceptability	Adoption	Appropriatenes s	Cost (High/	Feasibility	Fidelity	Penetration	Sustainability
		method	nPoC	РоС	=			low)				
Girdwood et al. (2020) Kenya	Quantitative study included all facilities	Geospatial cost outcome	GeneXpert	mPIMA				Low costs of PoC test to confirm treatme nt failure				Low sustainability of (n)PoC test in clinics with several challenges of staff availability and power
Vasconcellos et al. (2020) Brazil	Quantitative study included hospitals	Quantitative method		mPIMA					High feasibility of PoC due to collection of the low volume of plasma by fingerstick in sites without laboratory infrastruct ure			Low sustainability of (n)PoC test in clinics with several challenges of staff availability and power supply
Girdwood et al. (2019) Kenya 295	Quantitative study included remote healthcare facilities	Geospatial method	GeneXpert			(n)PoC test is adopted well since it is used for multi- disease testing	(n) PoC test produced results immediately					

Author/Year/ Country	Study design and setting	Collection	Type of PO	C test	Acceptability Ac	Adoption	s	(High/	Feasibility	Fidelity	Penetration	Sustainability
		method	nPoC	РоС				low)				
Simeon et al. (2019) South Africa	Randomized control trial included research and urban government clinic		GeneXpert	mPIMA				Low costs of PoC test in high testing volume clinics				
	Retrospective Cohort included four ART clinics and a district hospital	Quantitative method	SAMBA 1 VL		(n)PoC test mproved HIV care and reduced loss of follow-up							
De Necker et al. (2019) Kenya	Cohort modelling study	Quantitative method	GeneXpert					Low costs of (n)PoC test in monitori ng treatme nt failure				
Ndlovu et al. (2018) Zimbabwe	Prospective feasibility study in district hospital and rural primary healthcare facility	Quantitative method	GeneXpert			Multi- disease testing increases system efficiency	multi-disease testing	High costs of (n)PoC fail to manage samples in some clinics				

Author/Year/ Country	Study design and setting	Data Collection	Type of PO	C test	Acceptability	Adoption	Appropriatenes s	(High/	Feasibility	Fidelity	Penetration	Sustainability
		method	(n)PoC	PoC				low)				
Rasti et al. (2017) Western Uganda	Qualitative study included HC, regional and referral hospital	By Phone	GeneXpert		(n) PoC test improves the rapid treatment of patients after they receive results	interpreting			it strengthen s the	not implemented well due to distrust in test accuracy/lack		Low sustainability in clinic with poor documentation of results
Engel et al. (2017) South Africa	Purposive sampling included home, community, clinic, peripheral lab, hospital, a diagnostic company	Qualitative method	GeneXpert		Non- laboratory healthcare workers conducted the (n)PoC test					(n)PoC test was observed that HCWs were not aware and familiar with the guideline		7
Engel et al. (2015) South Africa	Purposive sampling in two urban and one rural setting	Qualitative method	GeneXpert		Patient adheres to medication. Multi-disease test evaluates multiple health conditions	Immediate provision of results and counselling to a patient			No delays in diagnosis and sufficient staffing to run the (n)PoC test		Nurses are supported in managing stable patients through guidelines. Manpower insufficient	sustainability of (n)PoC test in clinics with several challenges of staff availability and power supply

Author/Year/ Country	Study design and setting	Collection	Type of PO	C test	Acceptability Adoption A	s (Cost (High/	Feasibility	Fidelity	Penetration	Sustainability
		method		РоС			low)				
Estill et al. (2013) South Africa	Mathematical Modelling included township ART programs	Quantitative	GeneXpert				Low costs in (n)PoC test included the test to confirm treatme nt failure and shifting to second- line ART regimen				Sustainable when (n)PoC test costs are lowered

301 nPoC describes near point of care
 302 PoC VL describes point of care viral load
 303 HC describes health Centre

DH describes district hospital RH describes referral hospital ART describes Antiretroviral Therapy

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

Overall results We assessed the risk of bias with the Newcastle Ottawa Scale.(15) Fourteen studies had a low risk of bias (scored 7-9).(17,18,21-25,28-32,35,38) while ten studies had an unclear risk of bias (scored 4-6).(19,20,26,27,33,34,36,37,39,40) Only one study had a high risk of bias and scored 3; this was the prospective feasibility study conducted in Zimbabwe that highlighted potential bottlenecks.(41). The Newcastle Ottawa Scale completed in detail is available in the S4 Table. Each study described at least one of the eight IROs defined by Proctor et al.(13) Acceptability Ten studies described the acceptability of (n)PoC VL monitoring.(18–21,25,29,33,35,38,40) A study in Malawi, Uganda and South Africa (SA) on SAMBA I HIV, reported high satisfaction with (n)PoC VL monitoring, reduced turnaround times from blood draw to results and at the same time minimizing clinic visits for high-risk patients. (38,40) Further, in the STREAM study in SA, a retrospective cohort study on SAMBA 1 VL in Malawi, and a qualitative study in Southwestern Uganda, PoC or (n)PoC VL monitoring was highly acceptable to patients as it improves HIV care and ART adherence monitoring.(18–20) In addition, studies conducted in Ghana and Haiti using GeneXpert showed that (n)PoC VL monitoring was highly acceptable to patients with the added benefit of results on the same day, reduced drug resistance and immediate counselling.(21,25) Likewise, a qualitative study in SA and Zambia showed that (n)PoC or PoC VL monitoring was highly acceptable by health providers as it helps patients to accept their illness and adhere to medication. (29,33) However, low acceptability of (n)PoC VL monitoring was observed in the SA studies as nonlaboratory healthcare workers conducted (n)PoC tests.(29,35) Adoption Four studies described the adoption of (n)PoC VL monitoring.(20,29,30,41) Medical professionals and patients observed a high uptake of (n)PoC VL monitoring in studies conducted in SA. Kenya and Zimbabwe for its immediate provision of results and counselling to patients, including multi-disease testing, which increases system efficiency. (29,30,41) However,

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

in a qualitative study conducted in Southwestern Uganda, health staff observed low adoption of (n)PoC VL monitoring, coupled with limited knowledge regarding interpreting the results.(20) **Appropriateness** Appropriateness was touched upon in four studies.(30,32,40,41) A retrospective study in seven Sub-Saharan countries and the STREAM study in SA showed high appropriateness of (n)PoC VL monitoring as results were available at the near point of care.(32,40) In addition, a quantitative study in Kenya and the prospective feasibility study conducted in Zimbabwe revealed that (n)PoC testing with GeneXpert was highly appropriate for multi-disease testing as it provides immediate results(30,41) On the contrary, the second qualitative study done in SA observed a low appropriateness of (n)PoC VL monitoring in public health facilities with large numbers of people.(40) Costs Costs were described in nine studies.(17,23,27–29,31,33,36,41) An observational study of (n)PoC VL monitoring conducted in Kenya revealed high costs in low-testing volume clinics.(17) Researchers compared the (n)PoC costs with centralised testing, which were 54.93 USD per test and 25.65 USD per test respectively. The costs include personal time for a blood draw, clinical supplies, lab processing, training, lab equipment, electricity, rental space and cartridges. Furthermore, the feasibility study in Zimbabwe showed that (n)PoC VL monitoring had high costs due to failure to manage samples in some clinics.(41) A cohort study in SA and Zambia and quantitative studies in Kenya observed low costs of PoC VL monitoring that included both the confirmation of treatment failure and the transition to second-line ART regimens.(27,28,31,36) Also, qualitative studies in SA and Zambia showed low costs of PoC tests, as it was performed on the same day and on the spot.(29,33) In addition, a mixed method study in SA showed low costs of (n)PoC VL monitoring in high testing volume clinics.(23)

364 365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

Feasibility Feasibility was described in ten studies.(17,18,20,24,26,29,34,37–39) The SAMBA and feasibility studies in Malawi and Uganda using GeneXpert found that (n)PoC VL monitoring was more successful due to a reduction in time to results than centralised testing.(34,37,38) Similarly, a prospective study on the implementation of PoC maternal VL and Early infant diagnosis conducted in SA and the feasibility study in Malawi and Zimbabwe showed that GeneXpert used as a multi-disease testing tool, was highly feasible to scale up HIV testing.(26,39) Furthermore, the STREAM and the qualitative studies in SA and Southwestern Uganda found high feasibility of (n)PoC VL monitoring, enabling rapid diagnosis, which, when coupled with sufficient staffing, contributes to the improvement of healthcare. (18,20,29) Similarly, the quantitative study on developing and validating a simple and rapid way to generate a low volume of plasma used in PoC VL technology observed high feasibility in sites without laboratory Infrastructure.(24) However, low feasibility was observed in the Kenyan observational study in some settings that shared the same instrument, causing delays in VL results.(17) **Fidelity** Fidelity was described in three studies. (20,26,35) The qualitative study in Southwestern Uganda and the feasibility study in Malawi and Zimbabwe revealed that (n)PoC VL monitoring was not implemented accurately. This was due to clients' distrust in the accuracy of the tests and insufficient training for HCWs.(20,26) Also, the qualitative study in SA showed a low fidelity of (n)PoC VL monitoring as HCWs were not aware or familiar with the guidelines.(35) Penetration Three studies reported penetration.(29,38,39) The qualitative, prospective studies in SA reported high penetration of PoC or (n)PoC services when nurses are supported in managing stable patients through guidelines. (29,39) On the contrary, a qualitative study in SA and the SAMBA study in Malawi and Uganda observed low

395

396

397

398

399400

401

402

403

404

405

406

407

408

409

410

411

412

413414

415

416

417

418

419

420

421

422

423

424

penetration of the (n)PoC VL monitoring programme due to insufficient manpower and a high workload.(29,38) Sustainability Sustainability was described in six studies.(20,22,32,35,36,38) A retrospective study in Sub-Saharan African countries, STREAM and cost-effective studies in SA observed high sustainability of PoC or (n)PoC VL monitoring, by having clear diagnostic pathways in healthcare settings, ensuring increased utilisation and adequate patient care, especially when lowering PoC test costs.(22,32,36) On the other hand, the qualitative studies in Southwestern Uganda and SA and SAMBA studies in Malawi and Uganda observed low sustainability of (n)PoC VL monitoring in clinics, which is attributed to poor documentation of results, staff availability challenges and power supply.(20,35,38) **Discussion** This review has accumulated valuable insights into how PoC VL monitoring was implemented in various settings in LMICs and how specific implementation bottlenecks may limit proper implementation. Out of the twenty-five studies, fifteen studies specifically used GeneXpert for (n)PoC VL monitoring, six studies employed both GeneXpert and mPIMA, two studies used SAMBA 1 VL and only two studies focused on mPIMA PoC VL monitoring. The implementation outcomes of (n)PoC VL monitoring have been widely positive in most of the studies, with reported high satisfaction among patients and HCWs. The benefits reported include reduced turnaround time, minimised clinic visits for high-risk patients, improved HIV care and increased adherence monitoring to antiretroviral therapy (ART), which significantly contribute to the acceptance and uptake of (n)PoC VL monitoring. The short turnaround time of (n)PoC VL monitoring, providing same-day results was a key factor in its high acceptability. This led to early detection of treatment failure, minimised clinic visits, improved patient outcomes and minimised drug resistance. This was observed in a study conducted by Msimango et al., that (n)PoC VL monitoring was preferred and satisfactory over central laboratory testing as it reduced the frequency of clinic visits. (41)

This review shows that (n)PoC VL monitoring has improved the quality of HIV care from the

patient's perspective. Additionally, a study by Nicholas et al., with SAMBA 1 VL test, showed

427 that the same-day VL load test results improved HIV care and reduced follow-up loss.(19)

Moreover, PoC or (n)PoC VL monitoring has shown to lead to increased adherence monitoring

429 to ART. This was evident from a study in South Africa by Drain et al., in which patients

highlighted the advantages of MPIMA PoC or GeneXpert (n)PoC VL monitoring and that it

enhances the monitoring of adherence to Antiretroviral Treatment (ART).(18)

However, the adoption of PoC VL monitoring in various studies has been hindered by several

implementation bottlenecks. Challenges include issues related to non-laboratory HCWs not

knowing how to interpret the results well, making it difficult to integrate (n)PoC VL monitoring

into healthcare practices. This was also noted in a study by Wang et al., where HCWs lacked

training to implement (n)PoC VL monitoring tests effectively.(26)

Challenges also arose in terms of appropriateness in public health facilities, with large patient

volumes leading to delays in clinic flow. According to a study by Msimango et al., challenges

arose for the client, as (n)PoC tests may cause delays in clinic flow due to a high number of

people in the facility.(40)

Costs emerged as a barrier, particularly in low-volume clinics due to the high costs of (n)PoC VL

monitoring. The study by Simeon et al., noted that (n)PoC VL monitoring reduced its costs in

low-volume clinics when used for other disease testing as well. (23)

However, the complexity of multi-disease testing was identified as a challenge too in the review

studies. This was also reported by Bulterys et al., indicating that clinics with multi-disease

446 testing for (n)PoC VL monitoring using GeneXpert are accompanied by several challenges,

including multiple patient queues causing delays in results and extended clinic visits.(17)

Implementation of (n)PoC VL monitoring challenges including test accuracy, were identified.

Research by Rasti et al., found that patients were concerned about the diagnostic accuracy of

450 (n)PoC VL monitoring.(20)

Insufficient manpower and high workloads were recognised as obstacles. Engel et al. reported

452 that nurses perceived (n)PoC implementation as an extra workload, leading to patients' delays in

waiting for the results.(29)

454 To overcome these implementation bottlenecks, clear diagnostic pathways and proper 455 documentation of results were identified as essential measures to ensure the successful 456 implementation of PoC or (n)PoC VL monitoring. Also, studies showed that (n)PoC VL monitoring was acceptable and well adopted by patients 457 458 and HCWs due to multi-disease testing and delivery of same-day results.(21,30) On the other hand, PoC VL monitoring was shown to be cost-effective, appropriate and feasible when 459 460 conducted at the point of care.(24,32,33) This review has several limitations. The author considered only peer-reviewed published articles, 461 did not include unpublished reviews and the period for the included studies was restricted. 462 Studies published between 2013-2024 and limited databases were covered. The lack of data from 463 geographic regions outside of low- and middle-income countries raises a concern about bias and 464 the generalizability of the findings. 465 The strength of this review is that we used the Proctor framework, which gives a comprehensive 466 467 overview of implementation research outcomes. Gaps could suggest further research that can provide better insights into using PoC or (n)PoC VL monitoring in healthcare settings, human 468 469 resources, continuous staff training and sustainable supply chain of PoC or (n)PoC facilities. 470 471 Recommendations 472 Point of Care VL monitoring provides rapid results followed by adherence counselling compared to nPoC VL monitoring. Rapid results provided by PoC VL monitoring improved its 473 acceptability, leading to early detection of treatment failure, minimized clinic visits and 474 475 improved patient outcomes. To address the implementation challenges of (n)PoC VL monitoring, prioritisation of clear diagnostic pathways and proper documentation are needed, as identified in 476 477 this review. Further research should address gaps in healthcare settings, human resources, staff training and the sustainable supply chain for facilities that use (n)PoC tests. 478 479 **Conclusion** 480 Implementing PoC or (n)PoC testing for HIV VL monitoring was acceptable, feasible and can 481 reach a broad population. However, high costs, limited fidelity, and lack of penetration and 482 483 sustainability may hinder the use of the (n)PoC test in improving patient care and health

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

outcomes. Our findings indicate different implementation bottlenecks, such as non-laboratory HCWs not knowing how to interpret results and clinic delays due to high patient volumes. Additional challenges include increased costs due to low attendance, complex multi-disease testing and test accuracy concerns. Insufficient manpower and high workloads also affect implementation. Point of care knowledge and training are needed to address problems related to implementation outcomes. This enables researchers, public health communities and policymakers to collaborate effectively in developing and testing evidence-based interventions. **Acknowledgements** The authors thank the members of the EAPOC-VL study. The study is a collaboration between Uganda National Health Research Organisation/Uganda Virus Research Institute (UNHRO/UVRI, Uganda), Karolinska Institute (Sweden), The Good Samaritan Foundation Kilimanjaro Christian Medical Centre (GSF KCMC, Tanzania), Stichting Amsterdam Institute for Global Health and Development (AIGHD, the Netherlands), London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit, Uganda), National Institute for Medical Research (NIMR, Tanzania), Kenya Medical Research Institute (KEMRI), Center for Global Health Research (CGHR), and the University of Rwanda (UR, Rwanda).

514 References 515 516 Joint United Nations Programme on HIV/AIDS (UNAIDS) 2024. Fact sheet 2024 - Latest global and 517 regional HIV statistics on the status of the AIDS epidemic. 2024; Available from: 518 https://www.unaids.org/en 519 Lebelonyane R, Bachanas P, Block L, Ussery F, Alwano MG, Marukutira T, et al. To achieve 95-95-2. 520 95 targets we must reach men and youth: High level of knowledge of HIV status, ART coverage, 521 and viral suppression in the Botswana Combination Prevention Project through universal test and treat approach. PLoS One. 2021 Aug 1;16(8 August). 522 Carmona S, Peter T, Berrie L. HIV viral load scale-up: Multiple interventions to meet the HIV 523 3. 524 treatment cascade. Vol. 12, Current Opinion in HIV and AIDS. Lippincott Williams and Wilkins; 525 2017. p. 157-64. 526 4. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in 527 528 Uganda, August 2014-July 2015. BMC Infect Dis. 2017 May 3;17(1). 529 5. Considerations for adoption and use of multidisease testing devices in integrated laboratory 530 networks: information note. CCBY-NC-SA 30 IGO licence [Internet]. 2017;(June). Available from: 531 hhtps://iris.who.int/handle/10665/255693 532 6. Meeting Report. MOLECULAR DIAGNOSTICS INTEGRATION GLOBAL MEETING REPORT. African Soc Lab Med [Internet]. 2019;(10-12 JULY). Available from: http://apps.who.int/iris 533 Vojnov L, Taegtmeyer M, Boeke C, Markby J, Harris L, Doherty M, et al. Performance of non-534 7. 535 laboratory staff for diagnostic testing and specimen collection in HIV programs: A systematic 536 review and meta-analysis. Vol. 14, PLoS ONE. Public Library of Science; 2019. 537 8. Tun NN, Smithuis F, Tun NL, Min M, Hlaing MMM, van Olmen J, et al. Near point-of-care HIV viral 538 load testing: Cascade after high viral load in suburban Yangon, Myanmar. PLoS One. 2023 Apr 539 1;18(4 April). 540 Drain PK, Dorward J, Bender A, Lillis L, Marinucci F, Sacks J, et al. Point-of-Care HIV Viral Load 9. 541 Testing: an Essential Tool for a Sustainable Global HIV/AIDS Response [Internet]. 2019. Available 542 from: https://journals.asm.org/journal/cmr 543 10. Meggi B, Bollinger T, Zitha A, Mudenyanga C, Vubil A, Mutsaka D, et al. Performance of a True 544 Point-of-Care Assay for HIV-1/2 Viral Load Measurement at Antenatal and Postpartum Services 545 [Internet]. IMPLEMENTATION SCIENCE. 2021. Available from: www.jaids.com 546 11. Ritchie A V., Ushiro-Lumb I, Edemaga D, Joshi HA, De Ruiter A, Szumilin E, et al. SAMBA HIV 547 semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited 548 settings. J Clin Microbiol. 2014;52(9):3377-83. 549 12. Agutu CA, Ngetsa CJ, Price MA, Rinke de Wit TF, Omosa-Manyonyi G, Sanders EJ, et al. Systematic 550 review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and 551 care. PLoS One. 2018 Nov 1;14(6).

Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for

552

13.

- implementation research: Conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Heal Ment Heal Serv Res. 2011 Mar;38(2):65–76.
- 555 14. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting 556 items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and 557 explanation. Vol. 349, BMJ (Online). BMJ Publishing Group; 2015.
- Wells G, Shea B, Robertson J, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis.
- Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020
 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews.
 Vol. 372, The BMJ. BMJ Publishing Group; 2021.
- Bulterys MA, Oyaro P, Brown E, Yongo N, Karauki E, Wagude J, et al. Costs of point-of-care viral load testing for adults and children living with hiv in kenya. Diagnostics. 2021 Jan 1;11(1).
- Drain PK, Dorward J, Violette LR, Quame-Amaglo J, Thomas KK, Samsunder N, et al. Point-of-care
 HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM):
 findings from an open-label, non-inferiority, randomised controlled trial. Lancet HIV. 2020 Apr
 1;7(4):e229–37.
- Nicholas S, Poulet E, Wolters L, Wapling J, Rakesh A, Amoros I, et al. Point-of-care viral load
 monitoring: outcomes from a decentralized HIV programme in Malawi. J Int AIDS Soc.
 2019;22(8):1–9.
- 572 20. Rasti R, Nanjebe D, Karlström J, Muchunguzi C, Mwanga-Amumpaire J, Gantelius J, et al. Health 573 care workers' perceptions of point-of-care testing in a low-income country - A qualitative study in 574 Southwestern Uganda. PLoS One. 2017 Jul 1;12(7).
- Reif LK, Belizaire ME, Rouzier V, Seo G, Severe P, Bajo Joseph JM, et al. Point-of-care viral load testing among adolescents and young adults living with HIV in Haiti: a randomized control trial.

 AIDS Care Psychol Socio-Medical Asp AIDS/HIV. 2022;34(4):409–20.
- 578 22. Sharma M, Mudimu E, Simeon K, Bershteyn A, Dorward J, Violette LR, et al. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study. Lancet HIV. 2021 Apr 1;8(4):e216–24.
- 581 23. Simeon K, Sharma M, Dorward J, Naidoo J, Dlamini N, Moodley P, et al. Comparative cost analysis 582 of point-of-care versus laboratory-based testing to initiate and monitor HIV treatment in South 583 Africa. PLoS One. 2019 Oct 1;14(10).
- 584 24. Vasconcellos I, Mariani D, Azevedo MCVM d., Ferreira OC, Tanuri A. Development and validation 585 of a simple and rapid way to generate low volume of plasma to be used in point-of-care HIV virus 586 load technologies. Brazilian J Infect Dis. 2020 Jan 1;24(1):30–3.
- Villa G, Abdullahi A, Owusu D, Smith C, Azumah M, Sayeed L, et al. Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa. EClinicalMedicine. 2020 Jan 1;18.
- 590 26. Wang M, Boeke CE, Rioja MR, Maparo T, Banda C, Chavula C, et al. Feasibility and impact of near-591 point-of-care integrated tuberculosis/HIV testing in Malawi and Zimbabwe. AIDS. 2021 Dec 592 1;35(15):2531–7.

- 593 27. Broucker G De, Salvatore PP, Mutembo S, Moyo N, Mutanga JN, Thuma PE, et al. The cost-594 effectiveness of scaling-up rapid point-of-care testing for early infant diagnosis of HIV in southern 595 Zambia. PLoS One. 2021 Mar 1;16(3 March).
- de Necker M, de Beer JC, Stander MP, Connell CD, Mwai D. Economic and public health impact of decentralized HIV viral load testing: A modelling study in Kenya. PLoS One. 2019 Feb 1;14(2).
- 598 29. Engel N, Davids M, Blankvoort N, Pai NP, Dheda K, Pai M. Compounding diagnostic delays: A qualitative study of point-of-care testing in South Africa. Trop Med Int Heal. 2015 Apr 1;20(4):493–500.
- 601 30. Girdwood SJ, Nichols BE, Moyo C, Crompton T, Chimhamhiwa D, Rosen S. Optimizing viral load 602 testing access for the last mile: Geospatial cost model for point of care instrument placement. 603 PLoS One. 2019 Aug 1;14(8).
- 604 31. Girdwood SJ, Crompton T, Sharma M, Dorward J, Garrett N, Drain PK, et al. Cost-effectiveness of adoption strategies for point of care HIV viral load monitoring in South Africa. EClinicalMedicine. 2020 Nov 1;28.
- 807 32. Boeke CE, Joseph J, Atem C, Banda C, Coulibaly KD, Doi N, et al. Evaluation of near point-of-care viral load implementation in public health facilities across seven countries in sub-Saharan Africa. 2021; Available from: http://onlinelibrary.wiley.com/doi/10.1002/jia2.25663/full
- Tembo T, Dale H, Muttau N, Itoh M, Williamson D, Mwamba C, et al. "Testing Can Be Done Anywhere": A Qualitative Assessment of Targeted Community-Based Point-of-Care Early Infant Diagnosis of HIV in Lusaka, Zambia [Internet]. 2022. Available from: www.ghspjournal.org
- 813 34. Boyce RM, Ndizeye R, Ngelese H, Baguma E, Shem B, Rubinstein RJ, et al. It takes more than a machine: A pilot feasibility study of point-of-care HIV-1 viral load testing at a lower-level health center in rural western Uganda. PLOS Glob Public Heal. 2023 Mar 1;3(3).
- Engel N, Davids M, Blankvoort N, Dheda K, Pant Pai N, Pai M. Making HIV testing work at the point of care in South Africa: A qualitative study of diagnostic practices. BMC Health Serv Res. 2017;17(1).
- 619 36. Estill J, Egger M, Blaser N, Vizcaya LS, Garone D, Wood R, et al. Cost-effectiveness of point-of-care 620 viral load monitoring of antiretroviral therapy in resource-limited settings: Mathematical 621 modelling study. AIDS. 2013 Jun 1;27(9):1483–92.
- 622 37. Ganesh P, Heller T, Chione B, Gumulira J, Gugsa S, Khan S, et al. Near Point-of-Care HIV Viral 623 Load: Targeted Testing at Large Facilities [Internet]. 2020. Available from: www.jaids.com
- Gueguen M, Nicholas S, Poulet E, Schramm B, Szumilin E, Wolters L, et al. Implementation and operational feasibility of SAMBA I HIV-1 semi-quantitative viral load testing at the point-of-care in rural settings in Malawi and Uganda. Trop Med Int Heal. 2021 Feb 1;26(2):184–94.
- Kufa T, Mazanderani AH, Sherman GG, Elie Mukendi A, Murray T, Moyo F, et al. Point-of-care HIV maternal viral load and early infant diagnosis testing around time of delivery at tertiary obstetric units in South Africa: a prospective study of coverage, results return and turn-around times. J Int AIDS Soc 2020, 23e25487 [Internet]. 2020; Available from:
- http://onlinelibrary.wiley.com/doi/10.1002/jia2.25487/full
- 632 40. Msimango L, Gibbs A, Shozi H, Ngobese H, Humphries H, Drain PK, et al. Acceptability of point-of-

637

642

644

650

654

655

care viral load testing to facilitate differentiated care: a qualitative assessment of people living 633 with HIV and nurses in South Africa. BMC Health Serv Res. 2020 Dec 1;20(1). 635 Ndlovu Z, Fajardo E, Mbofana E, Maparo T, Garone D, Metcalf C, et al. Multidisease testing for HIV and TB using the GeneXpert platform: A feasibility study in rural Zimbabwe. PLoS One. 2018 636 Mar 1;13(3). 638 639 **Supporting information** 640 641 S1 Figure PRISMA Diagram S1 Table Search Strategy 643 S2 Table PRISMA checklists S3 Table Reasons for exclusions S4 Table Newcastle Ottawa Scale 645 646 647 648 649 **Authors' contributions** PM performed the literature search, screening, data extraction and analysis and constructed the 651 652 manuscript. MS performed the literature search, screening, data extraction and data analysis, review of articles, corrected the manuscript, IS reviewed the study results and final draft, KN 653 reviewed the introduction and final draft. RR reviewed and corrected the manuscript. AL performed the literature search, screening, data extraction and data analysis. AH corrected the 656 final manuscript. BM reviewed and corrected the final draft.




Figure 1: PRISMA diagram of studies screening and selection